S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% GOLD 4,023.00 +0.94% CRUDE 81.77 +3.57%
Next Bullish Trade
Sign in
REGN

Regeneron Pharmaceuticals, Inc. REGN

$676.69 -2.25 (-0.33%)
Extended · +1.46σ
+ Compare Open in Sniper

Price chart

Timeframe
Range
Fundamentals · free Click ▲ earnings markers (daily) for the day's move

Loading…

Latest bar · REGN

Momentum reads · latest daily bar
Last
$676.69
-2.25 (-0.33%)
Mkt cap
$70.9B
Healthcare
RSI(14)
62.0
neutral
Stochastic %K
84.5
overbought
MFI(14)
74.7
neutral
ADX(14)
30.6
trending

Green means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.

Financial overlay · last 12 quarters

The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 $3.6B $0.7B $0.7B $0.8B 20.2% 20.7%
2025-12-31 $3.9B $0.8B $0.9B $0.9B 21.7% 23.1%
2025-09-30 $3.8B $1.5B $1.1B $1.4B 38.9% 29.6%
2025-06-30 $3.7B $1.4B $1.1B $0.7B 37.9% 29.4%
2025-03-31 $3.0B $0.8B $0.6B $0.8B 26.7% 19.5%
2024-12-31 $nanB $nanB $nanB $nanB nan% nan%

Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.

Compare REGN vs peers

Line REGN up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.

Comparing REGN PFE×
Sector peers + LLY + UNH + JNJ + MRK + ABBV + TMO
Popular + AAPL + MSFT + NVDA + AMZN + GOOG + META + TSLA + AVGO
Matchups NVDA · AMD · AVGO · SMCI · MU AAPL · MSFT · GOOG · META · AMZN JPM · GS · MS · BAC · C TSLA · RIVN · LCID · GM · F XOM · CVX · OXY · COP
Verdict
Weighted score 0-100 across 2 tickers · best in green
#1
REGN
score 58.3
5/5 inputs
Growth score of 100 dominates with 19% revenue growth, offsetting weak momentum of negative 9.29% three-month performance.
value 33growth 100quality 67momentum 25sentiment 67
#2
PFE
score 41.7
5/5 inputs
Momentum leads at 75 with relatively strong recent performance, but growth score of zero from negative earnings drags overall ranking.
value 67growth 0quality 33momentum 75sentiment 33
REGN
Regeneron Pharmaceuticals, Inc.
$676.69
-0.33%
Snapshot
Price 676.69
Day % -0.33
1M % 10.08
3M % -9.29
YTD % -12.83
Market cap 70943522816.0
ADV ($) 679229620.0205688
Beta 0.236
OdysseyHQ zone
Current zone Extended
Dist 21-EMA % 3.74
Dist ATR (σ) 1.46
OdysseyHQ grade B
Confluence 4
Valuation
P/E (ttm) 16.585539
P/E (fwd) 12.363912
P/S 4.7550554
EV/EBITDA 14.328
P/B 2.1947296
FCF yield 0.0461
PEG 1.13
Growth
Revenue yoy 0.19
EPS yoy -0.072
FCF yoy —
Revenue trend 8Q
Quality
Gross margin 0.43885
Operating margin 0.20658001
Net margin 0.29648
ROE 0.14548
ROA 0.06126
Debt / Equity 0.09
Interest cov. 120.42
Technicals
RSI(14) 62.0
MACD signal bull
vs 50-DMA 4.78
vs 200-DMA -3.93
vs 52w high -17.59
HV-30 27.1
Sentiment
Analyst rec 1.75
Target upside 21.29
Insider buy-sell 90d -13
Risk
Short interest 3.52
Days to cover 3.2
Next earnings 2026-07-30
Full REGN dashboard →
PFE
PFE
$25.05
-0.36%
Snapshot
Price 25.05
Day % -0.36
1M % -3.8
3M % -7.97
YTD % -0.52
Market cap 142771077120.0
ADV ($) 1037779234.0927048
Beta 0.307
OdysseyHQ zone
Current zone Neutral
Dist 21-EMA % 1.53
Dist ATR (σ) 0.7
OdysseyHQ grade —
Confluence 0
Valuation
P/E (ttm) 19.122137
P/E (fwd) 8.8405
P/S 2.2549329
EV/EBITDA 7.648
P/B 1.5844401
FCF yield 0.0867
PEG 2.83
Growth
Revenue yoy 0.054
EPS yoy -0.101
FCF yoy —
Revenue trend 8Q
Quality
Gross margin 0.74801004
Operating margin 0.31617
Net margin 0.118310004
ROE 0.083100006
ROA 0.05687
Debt / Equity 0.72
Interest cov. 3.82
Technicals
RSI(14) 53.6
MACD signal neutral
vs 50-DMA -0.88
vs 200-DMA -3.23
vs 52w high -12.87
HV-30 23.5
Sentiment
Analyst rec 2.46429
Target upside 14.92
Insider buy-sell 90d 16
Risk
Short interest 2.87
Days to cover 3.45
Next earnings 2026-08-04
Full PFE dashboard →

Earnings replay · last 0 reports

How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.

No earnings history available.

Peer comparison · Healthcare

Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
REGN ★ $71B 16.5 12.4 4.8 14.4 2.2 43.9% 19.0% -7.2% 4.61%
LLY $1,051B 41.8 26.3 14.6 30.1 33.8 82.8% 55.5% 169.9% 0.87%
UNH $387B 32.1 19.2 0.9 20.2 4.0 18.8% 2.0% 0.7% 4.57%
JNJ $609B 29.4 19.7 6.2 18.4 7.5 68.1% 6.6% -1.0% —
MRK $315B 35.9 13.2 4.8 12.2 6.9 76.7% 4.9% — 4.46%
ABBV $450B 124.8 15.6 7.2 17.1 -67.6 72.0% 12.4% -46.2% 4.63%
PFE $143B 19.1 8.8 2.3 7.7 1.6 74.8% 5.4% -10.1% 8.67%
TMO $198B 29.3 19.5 4.4 21.4 3.8 40.9% 6.2% 11.3% 2.79%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.

Top institutional holders

Top-10 concentration: 41.27%

HolderShares% out
Blackrock Inc. 8,947,735 8.69%
Vanguard Capital Management LLC 6,654,913 6.46%
State Street Corporation 4,664,478 4.53%
Dodge & Cox Inc. 4,458,238 4.33%
JPMORGAN CHASE & CO 4,311,806 4.19%
Invesco Ltd. 3,905,109 3.79%
Franklin Resources, Inc. 2,722,071 2.64%
Geode Capital Management, LLC 2,607,732 2.53%
Price (T.Rowe) Associates Inc 2,177,527 2.11%
Nuveen, LLC 2,065,064 2.00%

Insider activity · 90d

0 buys / 13 sells · ratio 0.0 · Finnhub

  • RYAN ARTHUR F SELL 17,303 @ $650.15
  • RYAN ARTHUR F SELL 17,503 @ $714.13
  • RYAN ARTHUR F SELL 17,505 @ $712.09
  • RYAN ARTHUR F SELL 17,506 @ $711.49
  • RYAN ARTHUR F SELL 17,511 @ $710.87
  • RYAN ARTHUR F SELL 17,513 @ $709.45
  • RYAN ARTHUR F SELL 17,519 @ $707.40
  • RYAN ARTHUR F SELL 17,523 @ $706.74
  • RYAN ARTHUR F SELL 17,530 @ $705.56
  • RYAN ARTHUR F SELL 17,544 @ $704.28

Analyst estimates

Finnhub

What Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.

Low
$641.0
Mean
$820.7248
High
$1000.0
Analysts
27
Recommendation distribution · period 2026-07-01
9
18
11
Revision trend (2026-04-01 → 2026-07-01): net 30 → 27 -3 (net = strong_buy+buy − sell−strong_sell)

SEC filings

The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.

FormFiled DescriptionAction
4 2026-07-07 PRIMARY DOCUMENT view ·
8-K 2026-07-06 FORM 8-K view ·
8-K 2026-06-17 FORM 8-K view ·
13F-HR 2026-05-08 Institutional holdings (13F) view ·
4 2026-05-04 PRIMARY DOCUMENT view ·
10-Q 2026-04-29 10-Q view ·
8-K 2026-04-29 8-K view ·
DEF 14A 2026-04-24 DEFINITIVE PROXY STATEMENT view ·
8-K 2026-04-08 FORM 8-K view ·
4 2026-04-03 OWNERSHIP DOCUMENT view ·
4 2026-03-03 PRIMARY DOCUMENT view ·
4 2026-02-23 PRIMARY DOCUMENT view ·
4 2026-02-11 PRIMARY DOCUMENT view ·
4 2026-02-11 PRIMARY DOCUMENT view ·
13F-HR 2026-02-06 Institutional holdings (13F) view ·
10-K 2026-02-04 10-K view ·
8-K 2026-01-30 8-K view ·
8-K 2026-01-12 FORM 8-K view ·
4 2026-01-08 PRIMARY DOCUMENT view ·
4 2026-01-06 PRIMARY DOCUMENT view ·
4 2026-01-06 PRIMARY DOCUMENT view ·
4 2026-01-06 PRIMARY DOCUMENT view ·
4 2026-01-06 PRIMARY DOCUMENT view ·
4 2026-01-06 PRIMARY DOCUMENT view ·
4 2026-01-06 PRIMARY DOCUMENT view ·
4 2026-01-06 PRIMARY DOCUMENT view ·
4 2026-01-06 PRIMARY DOCUMENT view ·
4 2026-01-06 PRIMARY DOCUMENT view ·
4 2026-01-06 PRIMARY DOCUMENT view ·
4 2026-01-06 PRIMARY DOCUMENT view ·
4 2026-01-05 PRIMARY DOCUMENT view ·
4 2026-01-05 PRIMARY DOCUMENT view ·
4 2025-12-31 PRIMARY DOCUMENT view ·
4 2025-12-11 PRIMARY DOCUMENT view ·
4 2025-12-11 PRIMARY DOCUMENT view ·
4 2025-12-11 PRIMARY DOCUMENT view ·
4 2025-12-11 PRIMARY DOCUMENT view ·
4 2025-12-11 PRIMARY DOCUMENT view ·
4 2025-12-09 PRIMARY DOCUMENT view ·
4 2025-12-09 PRIMARY DOCUMENT view ·
4 2025-12-09 PRIMARY DOCUMENT view ·
4 2025-12-09 PRIMARY DOCUMENT view ·
4 2025-12-09 PRIMARY DOCUMENT view ·
4 2025-12-09 PRIMARY DOCUMENT view ·
4 2025-11-24 PRIMARY DOCUMENT view ·
4 2025-11-24 PRIMARY DOCUMENT view ·
4 2025-11-10 PRIMARY DOCUMENT view ·
13F-HR 2025-11-07 Institutional holdings (13F) view ·
4 2025-10-31 PRIMARY DOCUMENT view ·
4 2025-10-31 PRIMARY DOCUMENT view ·
10-Q 2025-10-28 10-Q view ·
8-K 2025-10-28 8-K view ·
8-K 2025-10-06 FORM 8-K view ·
13F-HR 2025-08-01 Institutional holdings (13F) view ·
10-Q 2025-08-01 10-Q view ·
8-K 2025-08-01 8-K view ·
8-K 2025-06-18 FORM 8-K view ·
13F-HR 2025-05-02 Institutional holdings (13F) view ·
10-Q 2025-04-29 10-Q view ·
8-K 2025-04-29 8-K view ·

About REGN

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology…

Options picks · REGN

ITM + OTM ideas from the latest scan

Loading…

Congress trades · REGN

STOCK Act disclosures

Loading…

SEC filings & insiders · REGN

EDGAR · live

Loading…

Holders · REGN

Institutions & insider activity

Loading…